Recent findings from multinational resistance surveys: are we 'PROTEKTed' from resistance?
Continual monitoring of antimicrobial resistance rates is essential. Several large surveillance programmes have been established, including the international, longitudinal, multi-centre study PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin). Initiated in 1999, PROTEKT monitors the antibacterial susceptibility of common respiratory tract pathogens. This article reviews the findings from PROTEKT to date and anticipates future trends in antimicrobial resistance. Data from PROTEKT indicate that resistance patterns for Streptococcus pneumoniae and Haemophilus influenzae are changing, with an increasing prevalence of multi-drug resistant genotypes. Resistance to the ketolide telithromycin is very rare, with rates of S. pneumoniae susceptibility remaining >99%. The in vitro activity of telithromycin remains at a high level irrespective of pathogen genotype or phenotype.
Marchese
Anna
A
Sezione di Microbiologia del Di.S.C.A.T., University of Genoa, Italy.
Schito
Gian Carlo
GC
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D048628:Ketolides / Q000494:pharmacology* / Q000627:therapeutic use; D011159:Population Surveillance; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000900:Anti-Bacterial Agents; D048628:Ketolides; C106791:telithromycin